BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms ...
In early 2024, Bayer announced topline data of the first two Phase 3 studies, OASIS 1 and 2 evaluating elinzanetant. Bayer's menopause drug elinzanetant was given the potential of about a billion ...
Imugene Ltd ((IUGNF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results